{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:15Z","timestamp":1758937215982,"version":"3.44.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.leukres.2021.106692","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T01:47:10Z","timestamp":1629510430000},"page":"106692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Venetoclax in combination with low dose Cytarabine and Actinomycin D for primary refractory acute myeloid leukemia patients failing intensive chemotherapy"],"prefix":"10.1016","volume":"111","author":[{"given":"Justinas","family":"Daraskevicius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6672-7358","authenticated-orcid":false,"given":"Veronika","family":"Everatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8949-3902","authenticated-orcid":false,"given":"Vilmante","family":"Vaitekenaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-4339","authenticated-orcid":false,"given":"Ugne","family":"Ringeleviciute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5549-0970","authenticated-orcid":false,"given":"Kazimieras","family":"Maneikis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrius","family":"Zucenka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Jul. (3)","key":"10.1016\/j.leukres.2021.106692_bib0005","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"issue":"Mar. (3)","key":"10.1016\/j.leukres.2021.106692_bib0010","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bbmt.2014.10.025","article-title":"The fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy","volume":"21","author":"Othus","year":"2015","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"issue":"Jun. (6)","key":"10.1016\/j.leukres.2021.106692_bib0015","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/leu.2017.23","article-title":"Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure","volume":"31","author":"Wattad","year":"2017","journal-title":"Leukemia"},{"issue":"May (5)","key":"10.1016\/j.leukres.2021.106692_bib0020","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/leu.2011.13","article-title":"Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia","volume":"25","author":"Craddock","year":"2011","journal-title":"Leukemia"},{"issue":"Jun. (11)","key":"10.1016\/j.leukres.2021.106692_bib0025","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.30536","article-title":"Allogeneic transplantation for advanced acute myeloid leukemia: the value of complete remission","volume":"123","author":"Weisdorf","year":"2017","journal-title":"Cancer"},{"issue":"Jun. (6)","key":"10.1016\/j.leukres.2021.106692_bib0030","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/leu.2017.23","article-title":"Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure","volume":"31","author":"Wattad","year":"2017","journal-title":"Leukemia"},{"issue":"Aug. (8)","key":"10.1016\/j.leukres.2021.106692_bib0035","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00277-020-04074-7","article-title":"Sequential allogeneic hematopoietic stem cell transplantation for active refractory\/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC","volume":"99","author":"Le Bourgeois","year":"2020","journal-title":"Ann. Hematol."},{"issue":"Sep. (9)","key":"10.1016\/j.leukres.2021.106692_bib0040","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3324\/haematol.2018.203869","article-title":"Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience","volume":"104","author":"Ram","year":"2019","journal-title":"Haematologica"},{"issue":"Feb. (6)","key":"10.1016\/j.leukres.2021.106692_bib0045","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"issue":"Jan. (11)","key":"10.1016\/j.leukres.2021.106692_bib0050","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3324\/haematol.2019.242826","article-title":"Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"105","author":"Bewersdorf","year":"2020","journal-title":"Haematologica"},{"issue":"May","key":"10.1016\/j.leukres.2021.106692_bib0055","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"Sep. (17)","key":"10.1016\/j.leukres.2021.106692_bib0060","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-10-0640","article-title":"Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines","volume":"16","author":"Xu","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"January","key":"10.1016\/j.leukres.2021.106692_bib0065","article-title":"Actinomycin D targets NPM1c-primed mitochondria to restore PML-driven senescence in AML therapy","author":"Wu","year":"2021","journal-title":"Cancer Discov."},{"issue":"July","key":"10.1016\/j.leukres.2021.106692_bib0070","first-page":"1","article-title":"Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation","author":"Zucenka","year":"2021","journal-title":"Bone Marrow Transplant."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:00Z","timestamp":1758934920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621001934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":14,"alternative-id":["S0145212621001934"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106692","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax in combination with low dose Cytarabine and Actinomycin D for primary refractory acute myeloid leukemia patients failing intensive chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106692"}}